RHÃN-KLINIKUM AG / Key word(s): Agreement/Miscellaneous 18.07.2011 08:30 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- RHÃN-KLINIKUM AG: - Particle therapy development project to be ended - Siemens fully compensates RKA for financial disadvantages - Revenue and earnings expectations for 2011 remain unchanged Bad Neustadt a. d. Saale, 18 July 2011 Under a partnership in Marburg, RHÃN-KLINIKUM AG and Siemens AG have been jointly developing a particle therapy facility. Based on a recent analysis of the project it has been found, contrary to the original expectations, that the technology is not yet sufficiently mature as to offer the prospect of sustained and economically feasible clinical operations within the foreseeable future. For this reason it has now been mutually decided to end the project. RHÃN-KLINIKUM AG and Siemens AG agreed that the financial disadvantages which arise for RHÃN-KLINIKUM AG will be compensated. At RHÃN-KLINIKUM AG the discontinuation of the project will result in impairments of EUR 17 million in financial year 2011. Given the undertaking of Siemens AG to make compensation payments, RHÃN-KLINIKUM AG will incur a non-operative extraordinary income amount in EBITDA which, on account of the corresponding impairments, will not have any impact on EBIT and net consolidated profit. The originally expected future earnings from the particle therapy facility are not material in relation to the total output of the RHÃN-KLINIKUM Group. For that reason, RHÃN-KLINIKUM AG does not expect the discontinuation of the project to have any materially adverse impact on its future net assets, financial position and results of operations. For financial year 2011, RHÃN-KLINIKUM AG continues to expect to generate revenues of approximately EUR 2.65 billion, a positive operating EBITDA of EUR 340 million and a net consolidated profit of approximately EUR 160 million, with the last two figures possibly fluctuating within a range of plus or minus 5%. The Board of Management Contact: Boris Tramm Head of Investor Relations RHÃN-KLINIKUM AG Schlossplatz 1 D-97616 Bad Neustadt a. d. Saale Tel.: 09771/ 65 - 1318 Fax: 09771/ 99 - 1736 E-mail: boris.tramm@rhoen-klinikum-ag.com 18.07.2011 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: RHÃN-KLINIKUM AG Schlossplatz 1 97616 Bad Neustadt a.d.Saale Germany Phone: +49 (0)9771 - 65-0 Fax: +49 (0)9771 - 97 467 E-mail: rka@rhoen-klinikum-ag.com Internet: www.rhoen-klinikum-ag.com ISIN: DE0007042301 WKN: 704230 Indices: MDAX Listed: Regulierter Markt in Frankfurt (Prime Standard), München; Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: RHÃN-KLINIKUM AG: Particle therapy development project to be ended
| Source: EQS Group AG